Evidence map›Paper›PMID 41906206›Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association2026

Exploring the gap between sensor-detected (SDH) and person-reported hypoglycaemia (PRH): The voice of people living with diabetes.

Monika Cigler, Omaima El-Hakouni, Renald Mecani, François Pouwer, Evertine J Abbink, Michaela Moser, Bastiaan E de Galan, Eric Renard, Mark Evans, Julie Maria Bøggild Brøsen and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Monika CiglerDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0001-5827-7991
Omaima El-HakouniDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0009-0009-1616-6711
Renald MecaniDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0003-2697-8544
François PouwerDepartment of Psychology, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0002-8172-9818
Evertine J AbbinkDepartment of Internal Medicine of Radboud University Medical Centre, Nijmegen, the Netherlands.ORCID https://orcid.org/0009-0006-5424-3704
Michaela MoserDepartment for Applied Computer Sciences/Business Informatics, FH Joanneum, Graz, Austria.ORCID https://orcid.org/0009-0009-7249-797X
Bastiaan E de GalanDepartment of Internal Medicine of Radboud University Medical Centre, Nijmegen, the Netherlands.ORCID https://orcid.org/0000-0002-1255-7741
Eric RenardMontpellier University Hospital, Montpellier, France.ORCID https://orcid.org/0000-0002-3407-7263
Mark EvansInstitute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0001-8122-8987
Julie Maria Bøggild BrøsenDepartment of Endocrinology and Nephrology, Copenhagen University Hospital, Hillerød, Denmark.ORCID https://orcid.org/0000-0001-7361-4407
Ulrik Pedersen-BjergaardDepartment of Endocrinology and Nephrology, Copenhagen University Hospital, Hillerød, Denmark.ORCID https://orcid.org/0000-0003-0588-4880
Rory J McCrimmonSchool of Medicine, University of Dundee, Dundee, UK.ORCID https://orcid.org/0000-0002-3957-1981
Simon HellerDivision of Clinical Medicine, School of Medicine and Public Health, University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0000-0002-2425-9565
Petra M BaumannDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0002-7665-0929
Uffe SøholmDepartment of Psychology, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0003-0848-9421
Silvia BastaDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0009-0008-5234-7547
Patrick DivillySt. Vincent's University Hospital, Dublin, University College Dublin, Dublin 4, Ireland.ORCID https://orcid.org/0000-0001-6916-3164
Natalie ZarembaDepartment of Diabetes, Faculty of Life Sciences and Medicine, King's College London, London, UK.ORCID https://orcid.org/0000-0002-1720-1621
Stephanie A AmielDepartment of Diabetes, Faculty of Life Sciences and Medicine, King's College London, London, UK.ORCID https://orcid.org/0000-0003-2686-5531
Pratik ChoudharyDiabetes Research Centre, University of Leicester, Leicester, UK.ORCID https://orcid.org/0000-0001-7635-4735
Julia K MaderDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.ORCID https://orcid.org/0000-0001-7854-4233
Hypo‐RESOLVE consortium

Funding

European CommissionEuropean Federation of Pharmaceutical Industries and AssociationsIHI
6 · The paper itself

Abstract

BACKGROUND AND

aimsIn people with insulin-treated diabetes experiencing hypoglycaemia, the multicentre Hypo-METRICS study found that 60% of sensor-detected hypoglycaemic episodes (SDH) were asymptomatic, and over 40% of person-reported hypoglycaemia (PRH) occurred at glucose levels ≥70 mg/dL (3.9 mmol/L). This subanalysis explored participants' experiences of these episodes to identify possible clinical implications.

methodsFifty-eight Austrian participants received a 15-item questionnaire on their experience of asymptomatic hypoglycaemia and symptoms at glucose levels ≥70 mg/dL (3.9 mmol/L).

resultsThe response rate was 86% (n = 50). Among all participants, 56% (n = 28) reported experiencing hypoglycaemic symptoms at glucose levels ≥70 mg/dL (3.9 mmol/L) "sometimes" or "often." They attributed this to a combination of a threshold shift due to chronic hyperglycaemia, rapid glucose decline and fear of hypoglycaemia. 68% of all SDH < 70 mg/dL and 59% of those below the clinically critical level of 54 mg/dL were asymptomatic.

conclusionThese results demonstrate that SDH and PRH each capture different, yet equally important, dimensions of the hypoglycaemia experience. Relying on only one source of information inevitably provides an incomplete picture. By integrating the patient's voice, diabetes professionals can provide appropriate support and tailor continuous glucose monitoring (CGM) alarm settings and treatment plans to truly meet individual needs.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HypoglycemiaHypoglycemic AgentsAdultAgedAustriaBlood GlucoseBlood Glucose Self-MonitoringContinuous Glucose MonitoringFemaleHumansInsulinMaleMiddle AgedSelf ReportBlood GlucoseHypoglycemic AgentsInsulincontinuous blood glucose monitoringdiabetespatient experiencetype 1 diabetestype 2 diabetes

Identifiers

PMID41906206
PMCPMC13380333

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.